[Successful treatment of myelodysplastic syndrome-associated autoinflammatory lymphedema with azacytidine]

Rinsho Ketsueki. 2019;60(12):1672-1675. doi: 10.11406/rinketsu.60.1672.
[Article in Japanese]

Abstract

An 84-year-old woman presented pancytopenia. She was diagnosed with myelodysplastic syndromes (MDS) with excess blasts-1, however, she declined treatment with azacitidine (AZA). Ten months later, bilaterally symmetrical, non-pitting edema appeared on the lower legs. A skin biopsy of the lower leg revealed lymphedema. The appearance and location of the lymphedema suggested an immunologic etiology; however, tests for autoimmune diseases yielded negative results. Therefore, a relationship between MDS and lymphedema was, therefore, speculated. Consequently, treatment with AZA was started, which led to marked improvement in both the lymphedema and pancytopenia. Based on the skin tissue pathology and the improvement in MDS after treatment with AZA, MDS-related autoinflammatory lymphedema was diagnosed.

Keywords: Autoinflammatory; Azacitidine; Lymphedema; Myelodysplastic syndromes.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Autoimmune Diseases*
  • Azacitidine
  • Female
  • Humans
  • Lymphedema*
  • Myelodysplastic Syndromes*
  • Pancytopenia*

Substances

  • Azacitidine